RETINAL SOLUTIONS LLC
Biotech · Private
Noregen, a norrin-derived growth factor therapeutic delivered via intravitreal injection to regenerate retinal blood vessels in ischemic retinopathies
- Grants
- $1.7M
- 3 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 15
- 9 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Noregen(TM), a regenerative medicine ocular therapeutic | $227,051 | |
| Federal grant | Department of Health and Human Services · Phase II · Noregen, a regenerative medicine ocular therapeutic | $717,783 | |
| Federal grant | Department of Health and Human Services · Phase II · Noregen, a regenerative medicine ocular therapeutic | $720,183 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2846 | Lomond Therapeutics | — | — |
| 2847 | Cardurion Pharmaceuticals | — | $350M |
| 2848 | DIGITAL NANOGENETICS, LLC | — | — |
| 2849 | RETINAL SOLUTIONS LLC | — | — |
| 2850 | Stipple Bio | — | $87M |
| 2851 | PPI PHARMACEUTICALS, LLC | — | — |
| 2852 | YOLO IMMUNE INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Norrin Induced Expression Of Genes And Use Thereof To Treat Diseasegranted
- Neural Regeneration With Synthetic Norrin Truncate Administrationapplication
- Synthetic Truncated Norrin Proteingranted
- FRIZZLED-4 Mutation Indicator Of Retinopathy And Intrauterine Growth Restrictiongranted
- Norrin Regulation Of Junction Proteins And The Use Thereof To Treat Epithelial Or Endothelial Membrane Leakage Induced Edemagranted
- Norrin Regulation Of Cellular Production Of Junction Proteins And Use To Treat Retinal Vasculature Edemagranted
- Retinal Capillary Regeneration With Synthetic Norrin Proteingranted
- Norrin Regulation Of Junction Proteins And The Use Thereof To Treat Epithelial Or Endothelial Membrane Leakage Induced Edemagranted
- Norrin Regulation Of Cellular Production Of Junction Proteins And Use To Treat Retinal Vasculature Edemagranted
- Method And Compositions For Genetic And Retinal Diseasegranted
- Methods And Compositions For Diagnosis And Treatment Of Genetic And Retinal Diseaseapplication
- Norrin Regulation Of Plasmalemma Vesicle-associated Protein And Use To Treat Macular Degenerationapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.